No headlines found.
No press releases found.
No news found.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
Advanced Biomed trades on the NASDAQ stock market under the symbol ADVB.
As of October 6, 2026, ADVB stock price climbed to $6.38 with 15,349 million shares trading.
ADVB has a beta of 0.70, meaning it tends to be less sensitive to market movements. ADVB has a correlation of 0.00 to the broad based SPY ETF.
ADVB has a market cap of $10.43 million. This is considered a Sub-Micro Cap stock.
ADVB has underperformed the market in the last year with a price return of -31.5% while the SPY ETF gained +17.6%. However, in the short term, ADVB had mixed performance relative to the market. It has outperformed in the last 3 months, returning +27.9% vs +4.9% return in SPY. But in the last 2 weeks, ADVB shares have been beat by the market, returning -1.4% compared to an SPY return of +0.7%.
ADVB support price is $5.88 and resistance is $6.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADVB shares will trade within this expected range on the day.
